Survodutide is a novel dual GLP?1 / glucagon receptor agonist peptide, developed for metabolic disorder related preclinical research. It is engineered to simultaneously activate GLP-1 receptors and glucagon receptors, integrating two distinct hormonal signaling pathways to regulate energy balance, glucose homeostasis and lipid metabolism, which makes it a powerful research tool for studying obesity, insulin resistance and hepatic metabolic pathways.

GLP?1 receptor activation primarily drives glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying and modulates central appetite regulation. Meanwhile, glucagon receptor agonism promotes hepatic lipolysis, increases energy expenditure and supports fat oxidation. The dual receptor activation profile of survodutide creates synergistic metabolic effects that are widely investigated in preclinical models. Laboratory studies focus on its impacts on body weight reduction, glycemic control, liver fat metabolism and energy expenditure regulation. Researchers utilize this peptide to explore the crosstalk between GLP-1 and glucagon signaling networks in adipocytes, hepatocytes, pancreatic islets and central nervous system.

Our Survodutide peptide is synthesized by solid-phase peptide synthesis (SPPS). After peptide chain assembly, cleavage and full deprotection, crude peptide is purified via preparative high-performance liquid chromatography to remove truncated sequences, residual protecting groups and process-related impurities. Every batch is subjected to mass spectrometry (MS) for molecular identity confirmation and HPLC analysis for purity verification. Extended quality control panel includes moisture content, residual solvent, heavy metal screening and microbial limit testing. Batch-wise COA documents with HPLC chromatogram and MS spectrum can be provided upon request. The lyophilized formulation greatly improves molecular stability during transportation and long-term cold preservation. After reconstitution, aliquot the peptide solution immediately. Short-term storage can be maintained at 2–8°C, while long-term storage requires -20°C. Repeated freeze-thaw cycles will induce peptide aggregation and loss of biological activity and should be strictly avoided.